Companies in the News

eFFECTOR Therapeutics Raises $40 Million Series B Financing

SAN DIEGO, December 22, 2015 – eFFECTOR Therapeutics, a biopharmaceutical company developing translation regulators for the treatment of cancer, today announced that it has received $40 million in a Series B financing following the advancement of its lead program toward clinical trials. The financing was led by Altitude Life Science Ventures and joined by AbbVie Biotech Ventures and BioMed Ventures. All of eFFECTOR’s existing investors, including Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners and Mission Bay Capital also participated in the round. The funds will support an open-label Phase 1/2 trial that will ev